Compare AEG & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | FMS |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | Netherlands | Germany |
| Employees | N/A | N/A |
| Industry | Life Insurance | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 13.6B |
| IPO Year | 1997 | 2005 |
| Metric | AEG | FMS |
|---|---|---|
| Price | $9.16 | $22.54 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 4.0M | 595.6K |
| Earning Date | 02-09-2023 | 05-05-2026 |
| Dividend Yield | ★ 4.68% | 2.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.83 |
| P/E Ratio | ★ $7.91 | $15.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.75 | $20.02 |
| 52 Week High | $9.64 | $27.64 |
| Indicator | AEG | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 33.29 |
| Support Level | $8.96 | $22.45 |
| Resistance Level | $9.24 | $22.59 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 46.59 | 13.92 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.